This Article contains typographical errors.
In the Results section under subheading ‘Impact of ZLD1039 on breast cancer cell growth’,
“Among the cell lines, MCF-7 and ZR-75-1 were the most sensitive to ZLD1039 with IC50 values of 0.99 ± 0.23 and 0.089 ± 0.019 μM, respectively”.
should read:
“Among the cell lines, MCF-7 and ZR-75-1 were the most sensitive to ZLD1039 with IC50 values of 0.99 ± 0.23 and 1.089 ± 0.019 μM, respectively”.
In Figure 3d, the x-axis ‘1–8 days of treatment’ was incorrectly given as ‘0–7 days of treatment’. The correct Figure 3d appears below as Fig. 1
Figure 1
Additional information
The online version of the original article can be found at 10.1038/srep20864
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Song, X., Gao, T., Wang, N. et al. Correction: Corrigendum: Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer. Sci Rep 6, 24893 (2016). https://doi.org/10.1038/srep24893
Published:
DOI: https://doi.org/10.1038/srep24893
This article is cited by
-
Tubular aryl hydratocarbon receptor upregulates EZH2 to promote cellular senescence in cisplatin-induced acute kidney injury
Cell Death & Disease (2023)
-
Selective EZH2 inhibitor zld1039 alleviates inflammation in cisplatin-induced acute kidney injury partially by enhancing RKIP and suppressing NF-κB p65 pathway
Acta Pharmacologica Sinica (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
